These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38657954)

  • 1. Loss to Follow up in Patients with Proliferative Diabetic Retinopathy Treated with Anti-VEGF Therapy and/or Panretinal Photocoagulation in the United States.
    Khurana RN; Wang JC; Zhang S; Li C; Lum F
    Ophthalmol Retina; 2024 Oct; 8(10):953-961. PubMed ID: 38657954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss to Follow-Up in Patients with Proliferative Diabetic Retinopathy after Panretinal Photocoagulation or Intravitreal Anti-VEGF Injections.
    Obeid A; Gao X; Ali FS; Talcott KE; Aderman CM; Hyman L; Ho AC; Hsu J
    Ophthalmology; 2018 Sep; 125(9):1386-1392. PubMed ID: 29606377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of Eyes Lost to Follow-up with Proliferative Diabetic Retinopathy That Received Panretinal Photocoagulation versus Intravitreal Anti-Vascular Endothelial Growth Factor.
    Obeid A; Su D; Patel SN; Uhr JH; Borkar D; Gao X; Fineman MS; Regillo CD; Maguire JI; Garg SJ; Hsu J
    Ophthalmology; 2019 Mar; 126(3):407-413. PubMed ID: 30077614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss to Follow-up in Patients with Neovascular Age-Related Macular Degeneration Treated with Anti-VEGF Therapy in the United States in the IRIS® Registry.
    Khurana RN; Li C; Lum F
    Ophthalmology; 2023 Jul; 130(7):672-683. PubMed ID: 36858288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial Therapy of Panretinal Photocoagulation vs Anti-VEGF Injection for Proliferative Diabetic Retinopathy.
    Alsoudi AF; Wai KM; Koo E; Parikh R; Mruthyunjaya P; Rahimy E
    JAMA Ophthalmol; 2024 Oct; 142(10):972-975. PubMed ID: 39207799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Vascular Endothelial Growth Factor and Panretinal Photocoagulation Use after Protocol S for Proliferative Diabetic Retinopathy.
    Azad AD; Chen EM; Hinkle J; Rayess N; Wu D; Eliott D; Mruthyunjaya P; Parikh R
    Ophthalmol Retina; 2021 Feb; 5(2):151-159. PubMed ID: 32693033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of Intravitreous Ranibizumab Compared With Panretinal Photocoagulation for Proliferative Diabetic Retinopathy: Secondary Analysis From a Diabetic Retinopathy Clinical Research Network Randomized Clinical Trial.
    Hutton DW; Stein JD; Bressler NM; Jampol LM; Browning D; Glassman AR;
    JAMA Ophthalmol; 2017 Jun; 135(6):576-584. PubMed ID: 28492920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab.
    Bressler SB; Beaulieu WT; Glassman AR; Gross JG; Jampol LM; Melia M; Peters MA; Rauser ME;
    Ophthalmology; 2017 Apr; 124(4):431-439. PubMed ID: 28161147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Factors Associated with Vision and Edema Outcomes.
    Bressler SB; Beaulieu WT; Glassman AR; Gross JG; Melia M; Chen E; Pavlica MR; Jampol LM;
    Ophthalmology; 2018 Nov; 125(11):1776-1783. PubMed ID: 29980333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
    Gross JG; Glassman AR; Liu D; Sun JK; Antoszyk AN; Baker CW; Bressler NM; Elman MJ; Ferris FL; Gardner TW; Jampol LM; Martin DF; Melia M; Stockdale CR; Beck RW;
    JAMA Ophthalmol; 2018 Oct; 136(10):1138-1148. PubMed ID: 30043039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term Treatment Patterns for Diabetic Macular Edema: Up to 6-Year Follow-up in the IRIS® Registry.
    Kuo BL; Tabano D; Garmo V; Kim E; Leng T; Hatfield M; LaPrise A; Singh RP
    Ophthalmol Retina; 2024 Nov; 8(11):1074-1082. PubMed ID: 38830485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-VEGF Therapy for Persistent Neovascularization after Complete Panretinal Photocoagulation in Proliferative Diabetic Retinopathy.
    Mehanna CJ; Abdul Fattah M; Haddad S; Tamim H; Ghazi N; Salti H
    Ophthalmol Retina; 2019 Jun; 3(6):473-477. PubMed ID: 31174668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Treatment Type and Loss to Follow-up With Tractional Retinal Detachment in Proliferative Diabetic Retinopathy.
    Tsui JC; Yu Y; VanderBeek BL
    JAMA Ophthalmol; 2023 Jan; 141(1):40-46. PubMed ID: 36454552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of Lost to Follow-Up in Patients Being Treated for Proliferative Diabetic Retinopathy.
    Green M; Tien T; Ness S
    Am J Ophthalmol; 2020 Aug; 216():18-27. PubMed ID: 32243878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression to Pars Plana Vitrectomy in Patients With Proliferative Diabetic Retinopathy.
    Alsoudi AF; Wai KM; Koo E; Parikh R; Mruthyunjaya P; Rahimy E
    JAMA Ophthalmol; 2024 Jul; 142(7):662-668. PubMed ID: 38842828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-vascular endothelial growth factor for proliferative diabetic retinopathy.
    Martinez-Zapata MJ; Martí-Carvajal AJ; Solà I; Pijoán JI; Buil-Calvo JA; Cordero JA; Evans JR
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD008721. PubMed ID: 25418485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five-Year Cost-effectiveness of Intravitreous Ranibizumab Therapy vs Panretinal Photocoagulation for Treating Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
    Hutton DW; Stein JD; Glassman AR; Bressler NM; Jampol LM; Sun JK;
    JAMA Ophthalmol; 2019 Dec; 137(12):1424-1432. PubMed ID: 31647496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disparities in Retinal Vein Occlusion Presentation and Initiation of Anti-VEGF Therapy: An Academy IRIS® Registry Analysis.
    Haller JA; Tomaiuolo M; Lucas MM; Yang CC; Hyman L;
    Ophthalmol Retina; 2024 Jul; 8(7):657-665. PubMed ID: 38278175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of anti-VEGF treatment on development of proliferative diabetic retinopathy in routine clinical practice.
    Moshfeghi AA; Khurana RN; Moini H; Sherman S; Reed K; Boucher N; Rahimy E
    BMC Ophthalmol; 2024 May; 24(1):229. PubMed ID: 38822279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.
    Bressler SB; Liu D; Glassman AR; Blodi BA; Castellarin AA; Jampol LM; Kaufman PL; Melia M; Singh H; Wells JA;
    JAMA Ophthalmol; 2017 Jun; 135(6):558-568. PubMed ID: 28448655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.